| scholarly article | Q13442814 |
| P356 | DOI | 10.4049/JIMMUNOL.1100539 |
| P8608 | Fatcat ID | release_uvmz7n66mzbh3cehbrkwcveuoq |
| P932 | PMC publication ID | 3150302 |
| P698 | PubMed publication ID | 21775681 |
| P5875 | ResearchGate publication ID | 51508241 |
| P50 | author | John M. Lachin | Q37391755 |
| Kevan C Herold | Q87494800 | ||
| P2093 | author name string | Zhugong Liu | |
| Lisa M Spain | |||
| Mark D Pescovitz | |||
| Kasia Bourcier | |||
| Paula McGee | |||
| Heidi Krause-Steinrauf | |||
| Adam Asare | |||
| Type 1 Diabetes TrialNet Anti-CD20 Study Group | |||
| H Michael Dosch | |||
| P2860 | cites work | Genetics, pathogenesis and clinical interventions in type 1 diabetes | Q28281029 |
| T cell activation and anergy to islet cell antigen in type I diabetes | Q28305536 | ||
| Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. | Q34052870 | ||
| A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses | Q34778834 | ||
| The role of B lymphocytes as key antigen-presenting cells in the development of T cell-mediated autoimmune type 1 diabetes | Q34984434 | ||
| B cells in autoimmune diabetes | Q35612697 | ||
| Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health | Q35632007 | ||
| B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice | Q36367653 | ||
| Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes | Q36906207 | ||
| B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice | Q37220772 | ||
| Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. | Q37400735 | ||
| Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. | Q38358439 | ||
| IFN-alpha and IL-10 induce the differentiation of human type 1 T regulatory cells. | Q40811244 | ||
| ICA69(null) nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide. | Q43829949 | ||
| ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease? | Q48563733 | ||
| Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis. | Q49071770 | ||
| Abnormal T-cell reactivities in childhood inflammatory demyelinating disease and type 1 diabetes. | Q53522198 | ||
| Persistent T cell anergy in human type 1 diabetes. | Q54070212 | ||
| Analysis of T-Cell Assays to Measure Autoimmune Responses in Subjects With Type 1 Diabetes | Q57158832 | ||
| Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell Function | Q57491711 | ||
| Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice | Q68123525 | ||
| Following a diabetogenic T cell from genesis through pathogenesis | Q70488192 | ||
| T helper cell subsets in insulin-dependent diabetes | Q72265872 | ||
| IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function | Q73062421 | ||
| B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice | Q73373664 | ||
| CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes | Q79843146 | ||
| Investigation of the role of B-cells in type 1 diabetes in the NOD mouse | Q80787816 | ||
| Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice | Q95789881 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type-1 diabetes | Q124407 |
| rituximab | Q412323 | ||
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1998-2005 | |
| P577 | publication date | 2011-07-20 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes | |
| P478 | volume | 187 |
| Q97682159 | A quantitative measure of treatment response in recent-onset type 1 diabetes |
| Q34380329 | Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesis |
| Q38021696 | Autoimmunity in 2011. |
| Q52623971 | B cell depletion reduces T cell activation in pancreatic islets in a murine autoimmune diabetes model. |
| Q38220863 | Biomarkers in type 1 diabetes: application to the clinical trial setting |
| Q64120222 | Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes |
| Q38071420 | Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus. |
| Q33413423 | Diabetes and immune thrombocytopenic purpura: a new association with good response to anti-CD20 therapy |
| Q37243204 | Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes |
| Q89170907 | Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes |
| Q47907621 | Have we pushed the needle for treatment of Type 1 diabetes? |
| Q38016902 | Immunologic and metabolic biomarkers of β-cell destruction in the diagnosis of type 1 diabetes |
| Q48000827 | Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development. |
| Q37490637 | Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice |
| Q37544980 | Large-scale prospective T cell function assays in shipped, unfrozen blood samples: experiences from the multicenter TRIGR trial |
| Q38385236 | Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes |
| Q36995568 | Life and death of β cells in Type 1 diabetes: A comprehensive review |
| Q36141999 | Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development |
| Q36650474 | New and future immunomodulatory therapy in type 1 diabetes |
| Q36807999 | Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes |
| Q34077400 | Recommendations for the definition of clinical responder in insulin preservation studies |
| Q38013105 | Red carpeting the newer antidiabetics |
| Q34227866 | Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline |
| Q38384138 | Reestablishing T Cell Tolerance by Antibody-Based Therapy in Type 1 Diabetes |
| Q44097749 | Restoring immune balance in type 1 diabetes |
| Q36430775 | Rituximab does not reset defective early B cell tolerance checkpoints |
| Q38679589 | Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies |
| Q88697599 | Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience |
| Q37006155 | Targeting regulatory T cells in the treatment of type 1 diabetes mellitus |
| Q37251153 | Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders |
| Q35180980 | The dual effects of B cell depletion on antigen-specific T cells in BDC2.5NOD mice |
| Q47577827 | The elusive role of B lymphocytes and islet autoantibodies in (human) type 1 diabetes |
| Q35787117 | The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes |
| Q38028889 | The long-term marriage between autoimmunity and internal medicine: a homage to Manuel Carlos Dias |
| Q88112314 | Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes |
| Q38117282 | Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes |
| Q28287737 | Type 1 diabetes: translating mechanistic observations into effective clinical outcomes |
Search more.